Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00086819" target="_blank" >RIV/00216224:14110/15:00086819 - isvavai.cz</a>

Alternative codes found

RIV/61989592:15110/15:33155457

Result on the web

<a href="http://dx.doi.org/10.1016/S1470-2045(15)00290-9" target="_blank" >http://dx.doi.org/10.1016/S1470-2045(15)00290-9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S1470-2045(15)00290-9" target="_blank" >10.1016/S1470-2045(15)00290-9</a>

Result language

angličtina

Original language name

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

Original language description

Background Currently, metastatic renal cell carcinoma is treated with sequential single agents targeting VEGF or mTOR. Here, we aimed to assess lenvatinib, everolimus, or their combination as second-line treatment in patients with metastatic renal cell carcinoma. Methods We did a randomised, phase 2, open-label, multicentre trial at 37 centres in five countries and enrolled patients with advanced or metastatic, clear-cell, renal cell carcinoma. We included patients who had received treatment with a VEGF-targeted therapy and progressed on or within 9 months of stopping that agent. Patients were randomised via an interactive voice response system in a 1:1:1 ratio to either lenvatinib (24 mg/day), everolimus (10 mg/day), or lenvatinib plus everolimus (18mg/day and 5 mg/day, respectively) administered orally in continuous 28-day cycles until disease progression or unacceptable toxic effects.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2015

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Lancet Oncology

ISSN

1470-2045

e-ISSN

—

Volume of the periodical

16

Issue of the periodical within the volume

15

Country of publishing house

US - UNITED STATES

Number of pages

10

Pages from-to

1473-1482

UT code for WoS article

000364470900030

EID of the result in the Scopus database

—